What is Pf-08049820 Mr2 used for?

Pf-08049820 Mr2 is indicated for Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Multiple Myeloma after at least 2 prior therapies, Relapsed or Refractory Multiple Myeloma after at least 3 prior therapies, Relapsed or Refractory Multiple Myeloma after at least 4 prior therapies.

Who makes Pf-08049820 Mr2?

Pf-08049820 Mr2 is developed by Pfizer.

What development phase is Pf-08049820 Mr2 in?

Pf-08049820 Mr2 is FDA-approved (marketed).

What is the generic name of Pf-08049820 Mr2?

pf-08049820-mr2 is the generic (nonproprietary) name of Pf-08049820 Mr2.

Last reviewed 2026-05-14 · How we verify

Pf-08049820 Mr2 (pf-08049820-mr2)

Pfizer · FDA-approved active Quality 40/100

At a glance

Generic name	pf-08049820-mr2
Sponsor	Pfizer
Drug class	Unknown
Target	Unknown
Therapeutic area	Oncology
Phase	FDA-approved

Approved indications

Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma after at least 2 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 3 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 4 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 5 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 6 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 7 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 8 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 9 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 10 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 11 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 12 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 13 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 14 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 15 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 16 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 17 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 18 prior therapies
Relapsed or Refractory Multiple Myeloma after at least 19 prior therapies

Common side effects

No common side effects on file.

Drug interactions

Warfarin
Aspirin
Pentobarbital
Phenobarbital
Rivaroxaban
Apixaban
Dabigatran
Clopidogrel
Ticagrelor
Prasugrel
Cilostazol
Dipyridamole

Key clinical trials

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pf-08049820 Mr2 CI brief — competitive landscape report
Pf-08049820 Mr2 updates RSS · CI watch RSS
Pfizer portfolio CI